trending Market Intelligence /marketintelligence/en/news-insights/trending/rv7ihlqb41ewelqqisilrq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Sarepta signs investment, licensing deal with Lacerta for gene therapy programs

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Sarepta signs investment, licensing deal with Lacerta for gene therapy programs

Sarepta Therapeutics Inc. signed investment and licensing agreements with privately held Lacerta Therapeutics Inc. for multiple gene therapy programs.

Under the agreement, Sarepta will make a $30 million equity investment in Lacerta and get a license to up to three central nervous system-targeted gene therapy programs, including exclusive rights to the gene therapy candidate for the metabolic disorder Pompe disease and options to two additional candidates.

Cambridge, Mass.-based Sarepta said that the transaction will expand its gene therapy pipeline to up to 11 unique candidates.

Alachua, Fla.-based Lacerta will manage the majority of preclinical development, while Sarepta will lead clinical development and commercialization of the product candidates.

Sarepta will owe development and sales-based milestones to Lacerta, along with royalties on net sales.